These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8737550)

  • 1. Dyslipidemia in chronic renal failure patients.
    Almeida AF; Gunjotikar RV; Chitalia V
    J Postgrad Med; 1994; 40(2):52-4. PubMed ID: 8737550
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypertriglyceridemia in chronic nonnephrotic renal failure.
    Gutman RA; Shalhoub RJ; Wade AD; O'Connell JM; Recant L
    Am J Clin Nutr; 1973 Feb; 26(2):165-72. PubMed ID: 4574031
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
    Corsini A; Holdaas H
    Ren Fail; 2005; 27(3):259-73. PubMed ID: 15957541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Disorders of lipid metabolism in patients with chronic renal failure and after kidney transplantation].
    Klin M
    Pol Tyg Lek; 1992 Aug 7-17; 47(31-33):667-70. PubMed ID: 1492031
    [No Abstract]   [Full Text] [Related]  

  • 5. Dyslipidemia in patients with chronic renal failure and in renal transplant patients.
    Shah B; Nair S; Sirsat RA; Ashavaid TF; Nair KG
    J Postgrad Med; 1994; 40(2):57-60. PubMed ID: 8737552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
    Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO
    Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid hormone and hyperlipemia of uremia.
    Drüeke T; Lacour B
    Contrib Nephrol; 1985; 49():12-9. PubMed ID: 3830562
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pathogenesis of hypertriglyceridemia in chronic uremia].
    Albertazzi A; Cappelli P; Spisni C; Del Rosso G; Di Paolo B; Palmieri PF; Evangelista M
    G Clin Med; 1980 Jul; 61(7):506-16. PubMed ID: 7450367
    [No Abstract]   [Full Text] [Related]  

  • 9. Does the modality of haemodialysis treatment affect lipoprotein composition?
    Blankestijn PJ; Joles JA; Koomans HA
    Nephrol Dial Transplant; 1996 Jan; 11(1):14-6. PubMed ID: 8649622
    [No Abstract]   [Full Text] [Related]  

  • 10. [Renal dyslipidemia in patients on chronic hemodialysis].
    Kovacić V; Sain M; Vukman V
    Lijec Vjesn; 2003; 125(3-4):77-80. PubMed ID: 12899098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Causes and risks of hyperlipidemia during dialysis and after renal transplantation].
    Verzola A; Perini L; Gatto S; Gilli P; Bedani PL
    Recenti Prog Med; 1998 Nov; 89(11):590-7. PubMed ID: 9844447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dyslipidemias in renal diseases: pathogenesis and treatment].
    Cuevas A; Maíz A; Arteaga A
    Rev Med Chil; 1998 Mar; 126(3):315-21. PubMed ID: 9674303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and treatment of dyslipidemia of renal diseases.
    Toto RD; Vega GL; Grundy SM
    Curr Opin Nephrol Hypertens; 1993 Sep; 2(5):784-90. PubMed ID: 7922219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sepsis in patients with terminal chronic kidney failure (a review of the literature)].
    Filiptsev PIa; Vetchinnikova ON; Cherniakov VL
    Khirurgiia (Mosk); 1988 Mar; (3):131-7. PubMed ID: 3290567
    [No Abstract]   [Full Text] [Related]  

  • 15. [What are the possibilities for treatment of hyperlipidemia in kidney insufficiency or in dialysis patients?].
    Grützmacher P; Scheuermann E
    Med Welt; 1982 Jun; 33(24):873-4. PubMed ID: 7109928
    [No Abstract]   [Full Text] [Related]  

  • 16. [Oral health in patients with chronic renal failure].
    Bots CP; Brand HS; Franse RL; van Nieuw AA
    Ned Tijdschr Tandheelkd; 2006 May; 113(5):182-5. PubMed ID: 16729562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of dietary modification on the lipid metabolism in patients with chronic renal failure (author's transl)].
    Tsukamoto Y; Okubo M; Marumo F; Yoneda T; Arai S; Homma Y; Nakamura H
    Nihon Jinzo Gakkai Shi; 1979 Feb; 21(2):111-21. PubMed ID: 470223
    [No Abstract]   [Full Text] [Related]  

  • 18. [Risk factors and cardiovascular disease in uremic patients].
    Valdés F; Morales JM
    Nefrologia; 2002; 22 Suppl 4():1-6. PubMed ID: 12123136
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hemostasis in uremic patients, significance of the Ivy test].
    Galvão MM; de Oliveira Stivanin HL; Langer B; Sabbaga E; de Góes GM
    Rev Hosp Clin Fac Med Sao Paulo; 1976; 31(6):442-5. PubMed ID: 796932
    [No Abstract]   [Full Text] [Related]  

  • 20. [Apolipoprotein C-II and C-III anomalies in normolipemic and hyperlipemic patients with chronic kidney failure].
    Tornero F; García-Garzón A; Rincón B; Prieto S; Usón J; Lozano L
    Nefrologia; 2000; 20(1):47-53. PubMed ID: 10822722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.